Abstract
Objective To estimate the age-standardised prevalence, awareness, treatment and control of hypertension; and to identify their risk factors in Bangladeshi adults 18 years and above using the Bangladesh Demographic and Health Survey (BDHS) 2017-18 data.
Methods Data from 12, 904 Bangladeshi adults aged 18 years and older available from the most recent nationally representative BDHS 2017-18 were used. Hypertension was defined as having systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg, and/or taking anti-hypertensive drugs to control blood pressure. Age-standardised prevalence of hypertension and control were estimated with direct standardisation, and a multilevel mixed-effects Poisson regression model with a robust variance was used to identify factors associated with hypertension and its awareness, treatment, and control.
Results The overall age-standardised prevalence of hypertension was 40.0% (95% CI, 38.9-42.2); (men: 37.1%, women: 42.0%). Among those with hypertension (n=3531), 44.3% were aware that they had the condition and 39.1% were taking anti-hypertensive medication. Among those treated for hypertension (n=1306), only 41% had controlled hypertension. Factors independently associated with hypertension were increasing age, higher body mass index, being women, having diabetes, and residing in selected administrative divisions. A declining trend of hypertension control was observed with increasing age and those not being educated.
Conclusion Hypertension is highly prevalent (4 out of 10) in Bangladeshi adults, while awareness, treatment, and control are low. Irrespective of risks associated with hypertension and its management, awareness and control programmes should be given high priority in reducing hypertension, and improving hypertension control in Bangladesh.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA as we used secondary survey data
Funding Statement
There was no funding available
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The survey, including biomarker measurements, was approved by the institutional review board at ICF and the Bangladesh Medical Research Council. Informed consent was obtained from all participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data can be available on request
